Compare ODC & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | PRME |
|---|---|---|
| Founded | 1941 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 553.2M |
| IPO Year | 1994 | 2022 |
| Metric | ODC | PRME |
|---|---|---|
| Price | $85.79 | $3.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.56 |
| AVG Volume (30 Days) | 82.7K | ★ 2.6M |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 50.45 | 18.18 |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | N/A | $47.01 |
| P/E Ratio | $50.79 | ★ N/A |
| Revenue Growth | 10.97 | ★ 55.28 |
| 52 Week Low | $45.61 | $2.67 |
| 52 Week High | $107.00 | $6.94 |
| Indicator | ODC | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 48.07 |
| Support Level | $85.61 | $3.16 |
| Resistance Level | $95.07 | $3.69 |
| Average True Range (ATR) | 2.45 | 0.23 |
| MACD | -0.37 | -0.01 |
| Stochastic Oscillator | 15.08 | 26.14 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.